Foghorn Therapeutics (FHTX) Reiterated at Buy by Stifel After Q4 Results

March 12, 2026 7:54 AM

Stifel analyst Laura Prendergast reiterated a Buy rating and $12.00 price target on Foghorn Therapeutics (NASDAQ: FHTX).The analyst commented, "On ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found